Favorable Outcome in Elderly Asian Patients with Metastatic Renal Cell Carcinoma Treated with Everolimus: The Osaka Urologic Oncology Group |
Inamoto, Teruo
(Department of Urology, Osaka Medical College)
Azuma, Haruhito (Department of Urology, Osaka Medical College) Nonomura, Norio (Department of Urology, Osaka University, Graduate School of Medicine) Nakatani, Tatsuya (Department of Urology, Osaka City University) Matsuda, Tadashi (Department of Urology, Kansai Medical University) Nozawa, Masahiro (Department of Urology, Kinki University School of Medicine) Ueda, Takeshi (Chiba Cancer Center) Kinoshita, Hidefumi (Department of Urology, Kansai Medical University) Nishimura, Kazuo (Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases) Kanayama, Hiro-Omi (Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School) Miki, Tsuneharu (Department of Urology, Kyoto Prefectural University of Medicine) Tomita, Yoshihiko (Department of Urology, Yamagata University, Faculty of Medicine) Yoshioka, Toshiaki (Sumitomo Hospital) Tsujihata, Masao (Osaka Rosai Hospital) Uemura, Hirotsugu (Department of Urology, Kinki University School of Medicine) |
1 | Atkins MB, Yasothan U, Kirkpatrick P (2009). Everolimus. Nat Rev Drug Discov, 8, 535-6. DOI ScienceOn |
2 | Bellmunt J, Eisen T, Fishman M, et al (2011). Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol, 78, 24-32. DOI ScienceOn |
3 | Bellmunt J, Flodgren P, Roigas J, et al (2009a). Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int, 104, 10-8. DOI ScienceOn |
4 | Bellmunt J, Guix M (2009b). The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int, 103, 572-7. DOI ScienceOn |
5 | Brenner H, Arndt V (2004). Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient. Cancer Causes Control, 15, 903-10. DOI ScienceOn |
6 | Eisen T, Sternberg CN, Robert C, et al (2012). Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst, 104, 93-113. DOI |
7 | Busch J, Seidel C, Kempkensteffen C, et al (2011). Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol, 60, 1163-70. DOI ScienceOn |
8 | Eisen T, Oudard S, Szczylik C, et al (2008). Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst, 100, 1454-63. DOI ScienceOn |
9 | Escudier B (2010). How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. J Clin Oncol, 28, 2125-6. DOI ScienceOn |
10 | Escudier B, Albiges L, Blesius A, et al (2010). How to select targeted therapy in renal cell cancer. Ann Oncol, 21, 59-62. DOI ScienceOn |
11 | Porta C, Calvo E, Climent MA, et al (2012). Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol, 61, 826-33. DOI ScienceOn |
12 | Reeve BB, Potosky AL, Smith AW, et al (2009). Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst, 101, 860-8. DOI ScienceOn |
13 | Siegel RL, Ward EM, Jemal A (2012). Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev, 21, 411-6. DOI ScienceOn |
14 | Anandappa G, Hollingdale A, Eisen T (2010). Everolimus a new approach in the treatment of renal cell carcinoma. Cancer Manag Res, 2, 61-70. |
15 | Calvo E, Escudier B, Motzer RJ, et al (2012). Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer, 48, 333-9. DOI ScienceOn |